Form 4 for ACRV Acrivon Therapeutics, Inc.
Accepted 2026-05-20 16:29:50 ET · period of report 2026-05-18 · accession 0000905148-26-002551 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-20 16:29 | 2026-05-18 | ACRV | Gamelin Erick | Chief Development Off | A - Grant | $0.00 | +38.6K | 53.0K | +268% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-18 | A | A | 38,584 | $0.00 | 52,992 | D | — | — | (F1) These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. |